Mario Eisenberger, MD
Enriched profileR. Dale Hughes Professor of Oncology, Johns Hopkins University School of Medicine · Johns Hopkins University School of Medicine
Mario Eisenberger is R. Dale Hughes Professor of Oncology, Johns Hopkins University School of Medicine at Johns Hopkins University School of Medicine. OpenAlex indexes 743 publications with 45,578 citations (h-index 90); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Mario Eisenberger, M.D., is R. Dale Hughes Professor of Oncology, Johns Hopkins University School of Medicine. The public record shows 743 publications with 45,578 citations (h-index 90), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Bone health and treatments. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 6 companies.
- Top research focus: Prostate Cancer Treatment and Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 255.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Presenter on systemic treatment of prostate cancer
President's Cancer Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Participant
World Health Organization panel on advanced prostate cancer clinical trials methodology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 18 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202515 payments$31,705openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20253 payments
- Veru Inc.Program year20244 payments$49,799openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Cytochrome P450 17A1 Inhibitor100%Abiraterone Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
157 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Most-cited works
by citation count (OpenAlex)- 01Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerArticle5,738 citations2004
- 02Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerArticle2,898 citations2015
- 03AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerArticle2,693 citations2014
- 04
- 05A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaArticle1,464 citations1989
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mario-eisenberger-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
cancer-matters.blogs.hopkinsmedicine.org/2020/07/23/cancer-matters-bill-nelson-advanced-prostate
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer-matters.blogs.hopkinsmedicine.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Federal University of Rio de Janeiro, Brazil
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Editorial & leadership roles
journal and society appointments- Medical Advisory Board Member
Tyme Technologies
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biospace.com ↗ - Ad-hoc Member
Oncologic Drugs Advisory Committee, FDA
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Member
American Association of Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Member
National Prostate Cancer Education Council
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Member
International Task Force of the American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Awards & honors
honors on the public record- America's Top Doctors
Castle Connolly
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - America's Top Doctors for Cancer
Castle Connolly
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Secondary affiliations
appointments beyond the home institution- Medical Oncologist
Sibley Memorial Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Professor of Urology
Johns Hopkins University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Media & interviews
press, podcasts and appearances- Cancer Matters podcast
Johns Hopkins Medicine - interview on advanced prostate cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer-matters.blogs.hopkinsmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)